Show Summary Details
- Preface
- Abbreviations
- Contributors
- Introduction
- Chapter 1 Global burden of diabetes and depression
- Chapter 2 A life course approach to understanding the association between depression and type 2 diabetes
- Chapter 3 MicroRNAs as novel biomarkers in depression, diabetes, and cardiovascular diseases
- Chapter 4 Genetics
- Chapter 5 Innate immunity and inflammation in type 2 diabetes-associated depression
- Chapter 6 Hypothalamic–pituitary–adrenal axis
- Chapter 7 Gut–brain axis: Physiology and pathology
- Chapter 8 Diabetes distress
- Chapter 9 The association between depression and cognitive impairment in type 2 diabetes
- Chapter 10 Treatment of depression in type 2 diabetes
- Chapter 11 Psychotropic drugs and metabolic risk
- Chapter 12 Metabolic surgery and depression
- Chapter 13 Novel pharmacological targets
- Chapter 14 Novel technologies: What does gastric electrical stimulation offer to the patient with type 2 diabetes and depression?
- Chapter 15 Current and emerging psychological models
- Chapter 16 Targeting the circadian system
- Chapter 17 Cultural and global perspectives
- Chapter 18 National and international policy initiatives on multimorbidity
- Index
(p. xi) Contributors
(p. xi)
Contributors
- Author(s):
Khalida Ismail
, Andreas Barthel
, Stefan R. Bornstein
, and Julio Licinio
Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.
Please subscribe or login to access full text content.
If you have purchased a print title that contains an access token, please see the token for information about how to register your code.
For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.
- Preface
- Abbreviations
- Contributors
- Introduction
- Chapter 1 Global burden of diabetes and depression
- Chapter 2 A life course approach to understanding the association between depression and type 2 diabetes
- Chapter 3 MicroRNAs as novel biomarkers in depression, diabetes, and cardiovascular diseases
- Chapter 4 Genetics
- Chapter 5 Innate immunity and inflammation in type 2 diabetes-associated depression
- Chapter 6 Hypothalamic–pituitary–adrenal axis
- Chapter 7 Gut–brain axis: Physiology and pathology
- Chapter 8 Diabetes distress
- Chapter 9 The association between depression and cognitive impairment in type 2 diabetes
- Chapter 10 Treatment of depression in type 2 diabetes
- Chapter 11 Psychotropic drugs and metabolic risk
- Chapter 12 Metabolic surgery and depression
- Chapter 13 Novel pharmacological targets
- Chapter 14 Novel technologies: What does gastric electrical stimulation offer to the patient with type 2 diabetes and depression?
- Chapter 15 Current and emerging psychological models
- Chapter 16 Targeting the circadian system
- Chapter 17 Cultural and global perspectives
- Chapter 18 National and international policy initiatives on multimorbidity
- Index